Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avai BioAVAI +13.93%22 3-Year Revenue Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates AVAI with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 2,568 Software companies, Avai Bio ranks worse than 38940.77% on this metric.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 9 years, the highest 3-Year average Revenue per Share Growth Rate of Avai Bio was -41.50% per year. The lowest was -41.50% per year. And the median was -41.50% per year.
Avai Bio (OTCPK:AVAI) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Avai Bio 3-Year Revenue Growth Rate Related Terms
AVAI vs FUSE, PAYD, BMR: 3-Year Revenue Growth Rate Comparison
For the Software - Application subindustry, Avai Bio's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avai Bio 3-Year Revenue Growth Rate vs Software Industry
For the Software industry and Technology sector, Avai Bio's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Avai Bio's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of 0.00% mean?
Avai Bio (AVAI) has a 3-Year Revenue Growth Rate of 0.00% as of Jun. 2026. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Avai Bio and its competitors. According to the industry distribution chart, Avai Bio ranks #999999 out of 2568 companies in the Software industry.
Is Avai Bio's 3-Year Revenue Growth Rate too high?
Avai Bio's current 3-Year Revenue Growth Rate is 0.00%. Based on the distribution chart, Avai Bio ranks #999999 out of 2568 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, Avai Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Avai Bio's 3-Year Revenue Growth Rate compare to FUSE and PAYD?
According to the Software industry distribution chart, Avai Bio ranks #999999 out of 2568 companies for 3-Year Revenue Growth Rate. This places Avai Bio in the lower half of its industry. The industry median 3-Year Revenue Growth Rate is 6.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Software company?
The median 3-Year Revenue Growth Rate among Software companies is 6.70, based on 2,568 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Avai Bio and its competitors. For the Software industry, the median 3-Year Revenue Growth Rate is 6.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avai Bio's current 3-Year Revenue Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avai Bio stock overvalued right now?
Avai Bio (AVAI) has a current 3-Year Revenue Growth Rate of 0.00%. The current 3-Year Revenue Growth Rate is 0.00%. Avai Bio's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For Avai Bio (AVAI), the current 3-Year Revenue Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avai Bio Inc is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements, developing cell-based therapies. The company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an ?-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments.
22GF Score
Get the complete analysis for AVAI
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVAI has been successfully added to your 
